Carasent Resultados de beneficios anteriores

Pasado controles de criterios 0/6

Los beneficios de Carasent han disminuido a una tasa media anual de -22.7%, mientras que en la industria Healthcare Services los beneficios crecieron en un 2.2% anualmente. Los ingresos han ido creciendo a una tasa media de 37.6% al año.

Información clave

-22.7%

Tasa de crecimiento de los beneficios

-15.6%

Tasa de crecimiento del BPA

Crecimiento de la industria Healthcare Services	2.9%
Tasa de crecimiento de los ingresos	37.6%
Rentabilidad financiera	-5.9%
Margen neto	-22.3%
Próxima actualización de resultados	12 Jul 2024

Actualizaciones de resultados anteriores recientes

Recent updates

Carasent ASA's (OB:CARA) Intrinsic Value Is Potentially 73% Above Its Share Price

May 11

Is Carasent ASA (OB:CARA) Potentially Undervalued?

Mar 18

Is Now The Time To Look At Buying Carasent ASA (OB:CARA)?

Nov 22

Carasent's (OB:CARA) Solid Profits Have Weak Fundamentals

May 06

Returns Are Gaining Momentum At Carasent (OB:CARA)

Apr 29

Carasent ASA Beat Analyst Profit Forecasts, And Analysts Have New Estimates

Feb 13

There Are Reasons To Feel Uneasy About Carasent's (OB:CARA) Returns On Capital

Nov 24

Calculating The Intrinsic Value Of Carasent ASA (OB:CARA)

May 23

We Like These Underlying Trends At Carasent (OB:CARA)

Feb 28

What Type Of Shareholders Own The Most Number of Carasent ASA (OB:CARA) Shares?

Jan 24

Desglose de ingresos y gastos
Beta

Cómo gana y gasta dinero Carasent. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).

Historial de beneficios e ingresos

OB:CARA Ingresos, gastos y beneficios (NOK Millions)
Fecha	Ingresos	Beneficios	Gastos G+A
31 Mar 24	251	-56	150
31 Dec 23	244	-46	146
30 Sep 23	235	-64	117
30 Jun 23	227	-49	106
31 Mar 23	210	5	84
31 Dec 22	195	31	65
30 Sep 22	179	47	98
30 Jun 22	168	15	87
31 Mar 22	154	33	75
31 Dec 21	137	0	62
30 Sep 21	117	-33	99
30 Jun 21	98	-21	89
31 Mar 21	83	-46	80
31 Dec 20	71	-38	73
30 Sep 20	64	-14	26
30 Jun 20	58	-4	24
31 Mar 20	52	3	23
31 Dec 19	48	3	22
30 Sep 19	44	2	20
30 Jun 19	40	0	19
31 Mar 19	35	-3	18
31 Dec 18	24	-7	15
30 Sep 18	14	12	16
30 Jun 18	6	18	12
31 Mar 18	0	19	7
31 Dec 17	0	20	6
30 Sep 17	25	128	-28
30 Jun 17	79	131	-4
31 Mar 17	136	139	22
31 Dec 16	194	142	50
30 Sep 16	205	3	10
30 Jun 16	234	56	51
31 Mar 16	259	56	69
31 Dec 15	305	61	94
30 Sep 15	322	-31	131
30 Jun 15	307	-80	100
31 Mar 15	314	-84	100
31 Dec 14	294	-79	91
30 Sep 14	255	2	64
30 Jun 14	248	2	63
31 Mar 14	246	3	66
31 Dec 13	254	5	72
30 Sep 13	256	7	73
30 Jun 13	263	9	80

Ingresos de calidad: CARA actualmente no es rentable.

Margen de beneficios creciente: CARA actualmente no es rentable.

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: CARA no es rentable, y las pérdidas han aumentado en los últimos 5 años a un ritmo de 14.5% al año.

Acelerando crecimiento: No se puede comparar el crecimiento de los beneficios de CARA en el último año con su promedio de 5 años, ya que actualmente no es rentable.

Beneficios vs. Industria: CARA no es rentable, por lo que resulta difícil comparar el crecimiento de sus beneficios en el último año con el de la industria Healthcare Services (11.7%).

Rentabilidad financiera

Alta ROE: CARA tiene una rentabilidad financiera negativa (-5.92%), ya que actualmente no es rentable.

Carasent Resultados de beneficios anteriores

Pasado controles de criterios 0/6

Información clave

Actualizaciones de resultados anteriores recientes

First quarter 2024 earnings released: kr0.15 loss per share (vs kr0.01 loss in 1Q 2023)

Full year 2023 earnings: EPS exceeds analyst expectations

Full year 2023 earnings: EPS exceeds analyst expectations

Carasent ASA to Report Fiscal Year 2023 Results on Mar 22, 2024

Second quarter 2023 earnings: EPS misses analyst expectations

First quarter 2023 earnings released: kr0.01 loss per share (vs kr0.32 profit in 1Q 2022)

Recent updates

Eg Norge A/S contemplates launching a voluntary cash offer to acquire Carasent ASA (OB:CARA) for NOK 1.4 billion.

Eg Norge A/S contemplates launching a voluntary cash offer to acquire Carasent ASA (OB:CARA) for NOK 1.4 billion.

First quarter 2024 earnings released: kr0.15 loss per share (vs kr0.01 loss in 1Q 2023)

Carasent ASA's (OB:CARA) 32% Jump Shows Its Popularity With Investors

New major risk - Share price stability

Carasent ASA Announces Changes to Its Board

Full year 2023 earnings: EPS exceeds analyst expectations

Chief Executive Officer recently bought kr1.4m worth of stock

Independent Director recently bought kr100k worth of stock

Full year 2023 earnings: EPS exceeds analyst expectations

Founder recently bought kr28m worth of stock

High number of new and inexperienced directors

Calculating The Fair Value Of Carasent ASA (OB:CARA)

Carasent ASA Announces Staffan Hanstorp Resigns as A Member of the Board of Directors

Carasent ASA to Report Fiscal Year 2023 Results on Mar 22, 2024

Chief Financial Officer recently bought kr165k worth of stock

Is It Too Late To Consider Buying Carasent ASA (OB:CARA)?

New minor risk - Share price stability

Carasent Asa Approves Dividend

Independent Director recently bought kr111k worth of stock

Upcoming dividend of kr1.84 per share

Price target decreased by 9.4% to kr29.00

Chief Executive Officer recently bought kr96k worth of stock

Carasent's (OB:CARA) Returns On Capital Are Heading Higher

Chief Executive Officer recently bought kr97k worth of stock

Second quarter 2023 earnings: EPS misses analyst expectations

Consensus EPS estimates upgraded to kr0.53 loss

Carasent ASA's (OB:CARA) Intrinsic Value Is Potentially 73% Above Its Share Price

Price target decreased by 12% to kr33.50

First quarter 2023 earnings released: kr0.01 loss per share (vs kr0.32 profit in 1Q 2022)

Is Carasent ASA (OB:CARA) Potentially Undervalued?

Full year 2022 earnings released: EPS: kr0.39 (vs kr0.002 loss in FY 2021)

Price target decreased by 8.6% to kr37.00

Carasent ASA to Report Q1, 2023 Results on May 04, 2023

Is Now The Time To Look At Buying Carasent ASA (OB:CARA)?

High number of new and inexperienced directors

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Consensus forecasts updated

Price target decreased to kr40.50

Carasent ASA (OB:CARA) acquired HPI Health Profile Institute AB for SEK 35 million.

Carasent ASA Provides Earnings Guidance for the Third Quarter and Full Year 2022

Carasent Asa Announces That Johan Lindqvist to Step Down as Chairman of the Board

Price target decreased to kr44.50

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Investor sentiment improved over the past week

Price target decreased to kr46.50

Investor sentiment improved over the past week

Consensus forecasts updated

Price target decreased to kr48.50

Carasent's (OB:CARA) Solid Profits Have Weak Fundamentals

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Returns Are Gaining Momentum At Carasent (OB:CARA)

Dennis Höjer Informs that He Will Step Down as CEO of Carasent ASA

No independent directors

Full year 2021 earnings: EPS misses analyst expectations

Carasent ASA Beat Analyst Profit Forecasts, And Analysts Have New Estimates

Full year 2021 earnings: EPS misses analyst expectations

Price target decreased to kr54.00

Carasent ASA (OB:CARA) completed the acquisition of Medrave Software AB.

Carasent ASA (OB:CARA) agreed to acquire Medrave Software AB for approximately SEK 130 million.

There Are Reasons To Feel Uneasy About Carasent's (OB:CARA) Returns On Capital

Price target increased to kr61.00

Third quarter 2021 earnings released: kr0.28 loss per share (vs kr0.21 loss in 3Q 2020)

Second quarter 2021 earnings released: EPS kr0.34 (vs kr0.14 loss in 2Q 2020)

Chief Financial Officer Lars Forsberg has left the company

Carasent ASA announced that it has received NOK 420.155987 million in funding from Cardigan Holdco S.à r.l.

Carasent ASA (OB:CARA) acquired Metodika AB for approximately SEK 110 million.

Calculating The Intrinsic Value Of Carasent ASA (OB:CARA)

First quarter 2021 earnings released: kr0.14 loss per share (vs kr0.01 profit in 1Q 2020)

Desglose de ingresos y gastos
Beta